Global Blood Gas and Electrolyte Analyzers Market to Reach USD 985 Million by 2026
|
By LabMedica International staff writers Posted on 30 Jun 2021 |

Illustration
The global blood gas and electrolyte analyzers market is projected to grow at a CAGR of 5.1% from an estimated USD 728.7 million in 2020 to USD 985 million by 2026, driven by improving infrastructure in diagnostic centers, hospitals and clinical laboratories, and a rise in the integration of critical equipment such as analyzers in ICUs, NICUs, and emergency and trauma units.
These are the latest findings of a new market study published by Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Blood gas and electrolyte analyzers are commonly used to test numerous parameters in the blood for identifying drug consumption, diabetes and blood vessel hemorrhage. The growth of the global blood gas and electrolyte analyzers market is being significantly boosted by the rising number of patients in critical care units and intensive care units (ICU); and the increasing demand for integrated, high-throughput systems that measure multiple parameters (such as creatinine, urea, nitrogen) in a short time, which is crucial for emergency situations. Another growth driver for the global market is the increasing adoption of these devices across hospitals, emergency wards and diagnostic centers. The growing relevance of point-of-care diagnosis within the healthcare industry due to its numerous advantages such as bedside care is poised to propel the market demand. Increasing spending on handheld, compact blood gas analyzers offering faster results and addressing needs of critical care services, operation rooms and emergency healthcare services will further boost global demand.
The Portable segment is projected to record a 5.8% CAGR to reach USD 681.6 million in 2026, while the Benchtop segment is expected to grow at a CAGR of 3.8% CAGR over the analysis period. The growing penetration of Point-of-Care (PoC) patient monitoring instruments, coupled with continued innovations and technology improvements taking place in the portable/handheld blood gas analyzers, is encouraging end users to switch over to the PoC version. Benchtop blood gas analyzer, also known as central laboratory analyzer, is generally placed in central laboratories of large hospitals, to undertake high volumes of blood gas testing. Due to the time critical nature of blood gas tests, especially in critical care departments, benchtop analyzers are moving out of the central laboratory and are being placed in near-patient locations in critical care areas such as ICU, CCU, ED, and OR.
Geographically, the US blood gas and electrolyte analyzers market is estimated to be valued at USD 223.1 million in 2021, driven by the demand for sophisticated medical infrastructure and favorable reimbursement plans of consumers in the region. The Chinese market for blood gas and electrolyte analyzers is projected to a record a CAGR of 6.5% over the analysis period to reach USD 111.7 million by 2026. Japan and Canada have been each forecasted to grow at a rate of 4.1% and 4.3%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 4.7%. The Asia-Pacific market holds high growth potential owing to its vast population, high unmet needs of patients, and higher disposable incomes. The introduction of favorable government initiatives, increasing prevalence of various chronic medical conditions and growing number of new hospitals is also expected to drive the growth of the blood gas and electrolyte analyzers market in Asia-Pacific.
Related Links:
Global Industry Analysts Inc.
These are the latest findings of a new market study published by Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Blood gas and electrolyte analyzers are commonly used to test numerous parameters in the blood for identifying drug consumption, diabetes and blood vessel hemorrhage. The growth of the global blood gas and electrolyte analyzers market is being significantly boosted by the rising number of patients in critical care units and intensive care units (ICU); and the increasing demand for integrated, high-throughput systems that measure multiple parameters (such as creatinine, urea, nitrogen) in a short time, which is crucial for emergency situations. Another growth driver for the global market is the increasing adoption of these devices across hospitals, emergency wards and diagnostic centers. The growing relevance of point-of-care diagnosis within the healthcare industry due to its numerous advantages such as bedside care is poised to propel the market demand. Increasing spending on handheld, compact blood gas analyzers offering faster results and addressing needs of critical care services, operation rooms and emergency healthcare services will further boost global demand.
The Portable segment is projected to record a 5.8% CAGR to reach USD 681.6 million in 2026, while the Benchtop segment is expected to grow at a CAGR of 3.8% CAGR over the analysis period. The growing penetration of Point-of-Care (PoC) patient monitoring instruments, coupled with continued innovations and technology improvements taking place in the portable/handheld blood gas analyzers, is encouraging end users to switch over to the PoC version. Benchtop blood gas analyzer, also known as central laboratory analyzer, is generally placed in central laboratories of large hospitals, to undertake high volumes of blood gas testing. Due to the time critical nature of blood gas tests, especially in critical care departments, benchtop analyzers are moving out of the central laboratory and are being placed in near-patient locations in critical care areas such as ICU, CCU, ED, and OR.
Geographically, the US blood gas and electrolyte analyzers market is estimated to be valued at USD 223.1 million in 2021, driven by the demand for sophisticated medical infrastructure and favorable reimbursement plans of consumers in the region. The Chinese market for blood gas and electrolyte analyzers is projected to a record a CAGR of 6.5% over the analysis period to reach USD 111.7 million by 2026. Japan and Canada have been each forecasted to grow at a rate of 4.1% and 4.3%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 4.7%. The Asia-Pacific market holds high growth potential owing to its vast population, high unmet needs of patients, and higher disposable incomes. The introduction of favorable government initiatives, increasing prevalence of various chronic medical conditions and growing number of new hospitals is also expected to drive the growth of the blood gas and electrolyte analyzers market in Asia-Pacific.
Related Links:
Global Industry Analysts Inc.
Latest Industry News
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more







